Skip to main content
Phase III Operations: The University is open for expanded research operations; only authorized personnel will be admitted on campus. More info here.

The Tri-Institutional Therapeutics Discovery Institute renews partnerships with Takeda and Bridge Medicines

The Rockefeller University, along with Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, today announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited (Takeda) and Bridge Medicines.

A pioneering academic-industry collaboration, the Tri-I TDI was established in 2013 to expedite early-stage drug discovery of novel therapies, including small molecules and biologics. To date, work done within the Tri-I TDI has resulted in the launch of two New York City–based companies and the licensing of six therapeutic discovery programs, with additional programs under active negotiation.

As the Tri-I TDI’s industry partner, Takeda contributes financial support, along with a wealth of drug discovery knowledge and expertise and best practices gained from its position as an established industry leader in the pharmaceutical sector.

In 2016, the Tri-I TDI announced the launch of Bridge Medicines in partnership with Takeda and healthcare investment firms Deerfield Management Company and Bay City Capital. Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded, and professionally staffed path from concept to drug candidate to efficiently develop innovative therapeutics for the treatment of human diseases.

Read the full press release here.

More news

Browse our recent stories.